<!DOCTYPE html>
<html lang="zh-Hant" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>巴菲特AI價值投資-Novo Nordisk 2025Q2 財務分析報告</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;500;700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Noto Sans TC', sans-serif;
            background-color: #f8fafc; /* stone-50 */
        }
        .active-nav-link {
            color: #0ea5e9; /* sky-500 */
            font-weight: 700;
            border-bottom: 2px solid #0ea5e9;
        }
        .inactive-nav-link {
            color: #44403c; /* stone-700 */
            border-bottom: 2px solid transparent;
        }
        .section-container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 2rem 1.5rem;
        }
        .card {
            background-color: white;
            border-radius: 0.75rem;
            box-shadow: 0 4px 6px -1px rgb(0 0 0 / 0.1), 0 2px 4px -2px rgb(0 0 0 / 0.1);
            padding: 1.5rem;
            margin-bottom: 1.5rem;
            transition: transform 0.2s ease-in-out, box-shadow 0.2s ease-in-out;
        }
        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 15px -3px rgb(0 0 0 / 0.1), 0 4px 6px -4px rgb(0 0 0 / 0.1);
        }
        .section-title {
            font-size: 1.875rem; /* text-3xl */
            font-weight: 700;
            color: #292524; /* stone-800 */
            margin-bottom: 1.5rem;
            border-bottom: 3px solid #0ea5e9; /* sky-500 */
            padding-bottom: 0.5rem;
        }
    </style>
</head>
<body class="text-stone-700">

    <!-- Header & Navigation -->
    <header class="bg-white/90 backdrop-blur-lg shadow-md sticky top-0 z-50">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex items-center justify-between h-20">
                <div class="flex items-center">
                    <a href="#" class="text-2xl font-bold text-sky-600">諾和諾德 2025Q2</a>
                </div>
                <div class="hidden md:block">
                    <nav id="desktop-nav" class="ml-10 flex items-baseline space-x-4">
                        <a href="#overview" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">公司概況</a>
                        <a href="#strategy" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">業務策略</a>
                        <a href="#metrics" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">營運指標</a>
                        <a href="#financials" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">財務表現</a>
                        <a href="#investment" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">投資與流動性</a>
                        <a href="#competition" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">競爭分析</a>
                        <a href="#risks" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">風險因素</a>
                        <a href="#summary" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">關鍵數據</a>
                        <a href="#assessment" class="nav-link inactive-nav-link px-3 py-2 rounded-md text-sm font-medium transition-colors duration-300">綜合評估</a>
                    </nav>
                </div>
                <div class="-mr-2 flex md:hidden">
                    <button id="mobile-menu-button" type="button" class="bg-stone-100 inline-flex items-center justify-center p-2 rounded-md text-stone-600 hover:text-stone-800 hover:bg-stone-200 focus:outline-none focus:ring-2 focus:ring-offset-2 focus:ring-offset-stone-100 focus:ring-sky-500">
                        <span class="sr-only">Open main menu</span>
                        <svg class="block h-6 w-6" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" aria-hidden="true">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16" />
                        </svg>
                    </button>
                </div>
            </div>
        </div>
        <!-- Mobile menu, show/hide based on menu state. -->
        <div id="mobile-menu" class="md:hidden hidden">
            <div class="px-2 pt-2 pb-3 space-y-1 sm:px-3">
                <a href="#overview" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">公司概況</a>
                <a href="#strategy" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">業務策略</a>
                <a href="#metrics" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">營運指標</a>
                <a href="#financials" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">財務表現</a>
                <a href="#investment" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">投資與流動性</a>
                <a href="#competition" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">競爭分析</a>
                <a href="#risks" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">風險因素</a>
                <a href="#summary" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">關鍵數據</a>
                <a href="#assessment" class="nav-link inactive-nav-link block px-3 py-2 rounded-md text-base font-medium">綜合評估</a>
            </div>
        </div>
    </header>

    <main>
        <!-- 1. 公司營運概況 -->
        <section id="overview" class="section-container">
            <h2 class="section-title">公司營運概況</h2>
            <div class="grid md:grid-cols-2 lg:grid-cols-3 gap-6">
                <div class="card lg:col-span-2">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">全球領先生物製藥公司</h3>
                    <p class="text-stone-600">諾和諾德是一家總部位於丹麥的全球領先生物製藥公司，在糖尿病和肥胖症治療領域擁有深厚積累。其主要業務包括糖尿病與肥胖症護理（涵蓋胰島素及GLP-1藥物）及罕見疾病治療，前者佔總營收約95%。公司在全球品牌糖尿病治療市場份額高達三分之一。</p>
                </div>
                <div class="card bg-sky-50 border-l-4 border-sky-500">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">核心業務佔比</h3>
                    <ul class="space-y-2 text-stone-600">
                        <li><span class="font-bold text-sky-600">95%</span>：糖尿病與肥胖症護理</li>
                        <li><span class="font-bold text-sky-600">5%</span>：罕見疾病藥物</li>
                    </ul>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">核心產品線：胰島素產品</h3>
                    <p class="text-stone-600">包含傳統人胰島素及現代胰島素類似物，如長效胰島素 Tresiba、門冬胰島素 NovoRapid 等。在胰島素領域擁有百年經驗，技術與規模領先全球。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">核心產品線：GLP-1 受體促效劑</h3>
                    <p class="text-stone-600">近年最具創新的產品類別，用於2型糖尿病和肥胖症治療。代表藥物包括 Ozempic®、Wegovy® 和口服片劑 Rybelsus®，是公司業績騰飛的關鍵。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">創新特色</h3>
                    <p class="text-stone-600">專注於糖尿病和相關代謝疾病的研發，並成功將成果拓展至新領域。率先將 GLP-1 藥物司美格魯肽應用於肥胖症治療，開創市場熱潮，並積極探索其在心血管風險、NASH 等新適應症的應用。</p>
                </div>
            </div>
        </section>

        <!-- 2. 業務策略和發展 -->
        <section id="strategy" class="section-container bg-white">
            <h2 class="section-title">業務策略和發展</h2>
            <div class="grid md:grid-cols-2 lg:grid-cols-4 gap-6">
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">產品研發與創新</h3>
                    <p class="text-stone-600">高度仰賴研發管線中的創新療法，推進如 CagriSema（雙激動劑）等下一代藥物，以鞏固市場領先地位。若能成功切入 NASH 等潛力市場，將開拓新的成長空間。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">全球市場擴張</h3>
                    <p class="text-stone-600">積極在更多地區推出核心產品，特別是新興市場如中國、印度。目前全球超過90%的糖尿病與肥胖患者生活在美國以外，開拓這些市場是未來營收成長的重要來源。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">提升市場滲透率</h3>
                    <p class="text-stone-600">目前 GLP-1 藥物僅佔全球糖尿病處方量約7%，肥胖症藥物治療率更低於1%。公司將持續投入市場教育，提高醫患接受度，並與保險機構合作擴大給付覆蓋面。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">產能擴充與策略併購</h3>
                    <p class="text-stone-600">投入巨資擴大丹麥和美國的工廠產能，以滿足全球龐大需求。同時進行策略性收購（如 Inversago Pharma），以強化產品線和獲取新技術平台。</p>
                </div>
            </div>
        </section>

        <!-- 3. 營運指標 -->
        <section id="metrics" class="section-container">
            <h2 class="section-title">營運指標</h2>
            <div class="grid md:grid-cols-2 lg:grid-cols-3 gap-6">
                <div class="card text-center bg-teal-50 border-t-4 border-teal-500">
                    <h3 class="text-4xl font-bold text-teal-600">1/3</h3>
                    <p class="mt-2 text-stone-600">全球品牌糖尿病治療市場份額</p>
                </div>
                <div class="card text-center bg-amber-50 border-t-4 border-amber-500">
                    <h3 class="text-4xl font-bold text-amber-600">9億+</h3>
                    <p class="mt-2 text-stone-600">全球肥胖人口潛在市場</p>
                </div>
                <div class="card text-center bg-indigo-50 border-t-4 border-indigo-500">
                    <h3 class="text-4xl font-bold text-indigo-600">&lt; 1%</h3>
                    <p class="mt-2 text-stone-600">目前使用品牌抗肥胖藥物治療的比例</p>
                </div>
                <div class="card text-center bg-rose-50 border-t-4 border-rose-500">
                    <h3 class="text-4xl font-bold text-rose-600">77,000+</h3>
                    <p class="mt-2 text-stone-600">截至2024年底全球員工人數 (五年內近翻倍)</p>
                </div>
                <div class="card text-center bg-lime-50 border-t-4 border-lime-500">
                    <h3 class="text-4xl font-bold text-lime-600">35個</h3>
                    <p class="mt-2 text-stone-600">Wegovy® 已上市國家數 (截至2025年)</p>
                </div>
                 <div class="card text-center bg-cyan-50 border-t-4 border-cyan-500">
                    <h3 class="text-4xl font-bold text-cyan-600">70%+</h3>
                    <p class="mt-2 text-stone-600">美國以外國際市場的GLP-1藥物市佔率</p>
                </div>
            </div>
        </section>

        <!-- 4. 財務表現細節 -->
        <section id="financials" class="section-container bg-white">
            <h2 class="section-title">財務表現細節</h2>
            <div class="grid lg:grid-cols-5 gap-6">
                <div class="lg:col-span-2">
                    <div class="card">
                        <h3 class="text-xl font-bold text-stone-800 mb-3">2025上半年業績亮眼</h3>
                        <p class="text-stone-600 mb-4">儘管下修全年預期，但2025上半年業績依然強勁，主要由糖尿病與肥胖症業務驅動。</p>
                        <ul class="space-y-3">
                            <li class="flex justify-between"><span>營收:</span> <span class="font-bold text-green-600">1,549.4億 DKK</span></li>
                            <li class="flex justify-between"><span>營收增長 (CER):</span> <span class="font-bold text-green-600">+18%</span></li>
                            <li class="flex justify-between"><span>營業利潤增長 (CER):</span> <span class="font-bold text-green-600">+29%</span></li>
                            <li class="flex justify-between"><span>肥胖症藥物銷售增長 (CER):</span> <span class="font-bold text-green-600">+58%</span></li>
                        </ul>
                    </div>
                    <div class="card bg-red-50 border-l-4 border-red-500">
                        <h3 class="text-xl font-bold text-stone-800 mb-3">下修全年財測</h3>
                        <p class="text-stone-600">公司意外下修2025全年成長預期，主因是擔憂GLP-1產品下半年增長趨緩、競爭加劇及市場滲透不如預期，引發市場震動，股價單日重挫。</p>
                        <ul class="space-y-2 mt-3">
                            <li><span class="font-semibold">營收增長預期:</span> 13%-21% <span class="text-red-600 font-bold">下修至 8%-14%</span></li>
                            <li><span class="font-semibold">營業利潤增長預期:</span> 16%-24% <span class="text-red-600 font-bold">下修至 10%-16%</span></li>
                        </ul>
                    </div>
                </div>
                <div class="lg:col-span-3 card">
                    <h3 class="text-xl font-bold text-stone-800 mb-4">2024 vs 2025 上半年財務概覽 (億 DKK)</h3>
                    <div class="h-96">
                        <canvas id="financialsChart"></canvas>
                    </div>
                </div>
            </div>
        </section>

        <!-- 5. 投資和流動性 -->
        <section id="investment" class="section-container">
            <h2 class="section-title">投資和流動性</h2>
            <div class="grid md:grid-cols-2 gap-6">
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">大規模產能擴充</h3>
                    <p class="text-stone-600">為滿足全球對 Wegovy® 等藥物的龐大需求，諾和諾德近年投入巨資擴大生產能力。這包括在丹麥本土和美國擴建工廠，並透過收購代工廠商 Catalent 的工廠來迅速提高供應能力。充足的產能是抓住市場機遇的必要條件。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">策略性併購與合作</h3>
                    <p class="text-stone-600">公司利用雄厚的現金流進行策略性收購以強化產品線和技術平台。例如，收購加拿大 Inversago Pharma 以獲取 GLP-1 療法的互補技術，以及收購 Dicerna 制藥以佈局 RNAi 療法。這些外延式舉措是公司成長的額外引擎。</p>
                </div>
            </div>
        </section>

        <!-- 6. 產業競爭分析 -->
        <section id="competition" class="section-container bg-white">
            <h2 class="section-title">產業競爭分析</h2>
            <div class="card mb-6">
                <h3 class="text-xl font-bold text-stone-800 mb-3">主要競爭對手：禮來公司 (Eli Lilly)</h3>
                <p class="text-stone-600">禮來是諾和諾德在 GLP-1 降糖及減重藥物市場最主要的競爭者。禮來推出的 Mounjaro/Zepbound (tirzepatide) 屬於雙激動劑，臨床數據顯示減重效果出眾，已在美國市場對諾和諾德的 Wegovy 構成強大壓力，導致其市佔率面臨被趕超的風險。</p>
            </div>
             <div class="card">
                <h3 class="text-xl font-bold text-stone-800 mb-3">GLP-1 藥物市場主要產品比較</h3>
                 <div class="mb-4">
                    <input type="text" id="table-filter" class="w-full md:w-1/3 p-2 border border-stone-300 rounded-lg focus:ring-2 focus:ring-sky-500 focus:border-sky-500" placeholder="篩選藥物、公司或特色...">
                </div>
                <div class="overflow-x-auto">
                    <table class="w-full text-left border-collapse">
                        <thead class="bg-stone-100">
                            <tr>
                                <th class="p-3 font-bold uppercase text-stone-600 border-b border-stone-200">藥物商品名</th>
                                <th class="p-3 font-bold uppercase text-stone-600 border-b border-stone-200">公司</th>
                                <th class="p-3 font-bold uppercase text-stone-600 border-b border-stone-200">通用名</th>
                                <th class="p-3 font-bold uppercase text-stone-600 border-b border-stone-200">機制</th>
                                <th class="p-3 font-bold uppercase text-stone-600 border-b border-stone-200">主要特色</th>
                            </tr>
                        </thead>
                        <tbody id="competitor-table">
                            <tr class="hover:bg-stone-50">
                                <td class="p-3 text-stone-800 border-b border-stone-200">Wegovy® / Ozempic®</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">諾和諾德</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">Semaglutide</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">GLP-1 受體促效劑</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">市場先驅，心血管獲益數據支持</td>
                            </tr>
                            <tr class="hover:bg-stone-50">
                                <td class="p-3 text-stone-800 border-b border-stone-200">Zepbound® / Mounjaro®</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">禮來</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">Tirzepatide</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">雙激動劑 (GLP-1/GIP)</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">減重效果數據優異，強勢後起之秀</td>
                            </tr>
                             <tr class="hover:bg-stone-50">
                                <td class="p-3 text-stone-800 border-b border-stone-200">Rybelsus®</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">諾和諾德</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">Semaglutide</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">GLP-1 受體促效劑</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">首款口服 GLP-1 藥物</td>
                            </tr>
                             <tr class="hover:bg-stone-50">
                                <td class="p-3 text-stone-800 border-b border-stone-200">Orforglipron (研發中)</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">禮來</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">Orforglipron</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">口服小分子 GLP-1</td>
                                <td class="p-3 text-stone-800 border-b border-stone-200">每日口服，潛在的便捷性優勢</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
        </section>

        <!-- 7. 風險和不確定性 -->
        <section id="risks" class="section-container">
            <h2 class="section-title">風險和不確定性</h2>
            <div class="grid md:grid-cols-2 lg:grid-cols-3 gap-6">
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">競品威脅與市占流失</h3>
                    <p class="text-stone-600">最大風險來自禮來等對手的產品超越。若禮來的新藥在效果或便捷性上更優，諾和諾德恐將面對市佔率被蠶食的局面。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">政策監管與定價壓力</h3>
                    <p class="text-stone-600">美國等市場的藥價管制風險正上升，可能對高價的 GLP-1 藥物施加價格上限或談判降價，從而影響利潤。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">市場增長放緩</h3>
                    <p class="text-stone-600">肥胖藥市場長期增長斜率可能趨緩。公司已感受到2025下半年市場擴張有「滯後」之虞，需防範增長低於預期的風險。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">供應與生產風險</h3>
                    <p class="text-stone-600">儘管大力擴產，但供應鏈中斷風險依然存在，如關鍵原料短缺或製造品質問題，可能造成產品供不應求。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">法律與商譽風險</h3>
                    <p class="text-stone-600">隨著藥物大量使用，可能出現新的不良事件報告引發集體訴訟。此外，核心專利被挑戰或任何負面新聞都可能傷害商譽。</p>
                </div>
                 <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">非正規競品干擾</h3>
                    <p class="text-stone-600">美國市場出現複方藥局配製的「山寨版」司美格魯胺，以低價吸引需求，衝擊公司在美國的增長。</p>
                </div>
            </div>
        </section>

        <!-- 8. 關鍵數據匯總及財務指引 -->
        <section id="summary" class="section-container bg-white">
            <h2 class="section-title">關鍵數據匯總及財務指引</h2>
            <div class="grid md:grid-cols-2 lg:grid-cols-4 gap-6">
                <div class="card bg-blue-50">
                    <h3 class="text-lg font-semibold text-blue-800 mb-2">2025 H1 營收</h3>
                    <p class="text-3xl font-bold text-blue-600">1,549.4 億</p>
                    <p class="text-sm text-stone-500">丹麥克朗 (DKK)</p>
                </div>
                <div class="card bg-green-50">
                    <h3 class="text-lg font-semibold text-green-800 mb-2">2025 H1 營收增長</h3>
                    <p class="text-3xl font-bold text-green-600">+18%</p>
                    <p class="text-sm text-stone-500">按固定匯率 (CER)</p>
                </div>
                <div class="card bg-red-50">
                    <h3 class="text-lg font-semibold text-red-800 mb-2">2025 全年營收指引</h3>
                    <p class="text-3xl font-bold text-red-600">8% - 14%</p>
                    <p class="text-sm text-stone-500">原為 13% - 21%</p>
                </div>
                <div class="card bg-yellow-50">
                    <h3 class="text-lg font-semibold text-yellow-800 mb-2">市值波動</h3>
                    <p class="text-3xl font-bold text-yellow-600">~50%</p>
                    <p class="text-sm text-stone-500">自高點回落</p>
                </div>
            </div>
        </section>

        <!-- 9. 綜合評估 -->
        <section id="assessment" class="section-container">
            <h2 class="section-title">綜合評估</h2>
            <div class="grid md:grid-cols-2 gap-6">
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">偏向「成長型」投資標的</h3>
                    <p class="text-stone-600">諾和諾德兼具價值與成長特質，但目前更偏向「成長型」標的。其主要看點在於高速增長的肥胖症與GLP-1產品，營收增幅遠超傳統大型藥企。高成長預期也帶來較高的估值和股價波動性。公司將資源重點投入研發和擴張，而非高比例現金回饋股東，這也符合成長型公司的特點。</p>
                </div>
                <div class="card">
                    <h3 class="text-xl font-bold text-stone-800 mb-3">適合的投資人類型</h3>
                    <ul class="list-disc list-inside space-y-2 text-stone-600">
                        <li><span class="font-semibold">成長型投資人：</span>尋求資本增值，看重其在肥胖症革命中的領軍地位，並能接受股價的較大起伏。</li>
                        <li><span class="font-semibold">長期佈局型投資人：</span>看重公司的長期競爭優勢（寬護城河）和醫療需求的持久性，可將短期回調視為買入良機。</li>
                        <li><span class="font-semibold">主題投資者：</span>關注醫療保健趨勢或「肥胖經濟」主題的投資者，諾和諾德是該領域的核心標的。</li>
                    </ul>
                    <p class="mt-4 text-sm text-stone-500">註：對於追求穩定股息、低波動的極保守投資者，諾和諾德未必是首選。</p>
                </div>
            </div>
        </section>
    </main>
    
    <footer class="bg-stone-800 text-white mt-12">
        <div class="max-w-7xl mx-auto py-6 px-4 sm:px-6 lg:px-8 text-center text-sm">
            <p>&copy; 巴菲特AI價值投資-Novo Nordisk 2025Q2 財務分析報告。僅供參考，不構成投資建議。</p>
            <p class="text-xs mt-1">資料來源：基於網路中Novo Nordisk相關公開資料 (2025年8月21日)。</p>
        </div>
    </footer>

<script>
document.addEventListener('DOMContentLoaded', function () {
    // Mobile Menu Toggle
    const mobileMenuButton = document.getElementById('mobile-menu-button');
    const mobileMenu = document.getElementById('mobile-menu');
    mobileMenuButton.addEventListener('click', () => {
        mobileMenu.classList.toggle('hidden');
    });

    // Intersection Observer for Active Nav Link
    const sections = document.querySelectorAll('section');
    const navLinks = document.querySelectorAll('.nav-link');

    const observerOptions = {
        root: null,
        rootMargin: '0px',
        threshold: 0.4 // When 40% of the section is visible
    };

    const observer = new IntersectionObserver((entries, observer) => {
        entries.forEach(entry => {
            if (entry.isIntersecting) {
                const id = entry.target.getAttribute('id');
                navLinks.forEach(link => {
                    link.classList.remove('active-nav-link');
                    link.classList.add('inactive-nav-link');
                    if (link.getAttribute('href') === `#${id}`) {
                        link.classList.add('active-nav-link');
                        link.classList.remove('inactive-nav-link');
                    }
                });
            }
        });
    }, observerOptions);

    sections.forEach(section => {
        observer.observe(section);
    });

    // Interactive Table Filter
    const filterInput = document.getElementById('table-filter');
    const tableRows = document.querySelectorAll('#competitor-table tr');

    filterInput.addEventListener('input', (e) => {
        const searchTerm = e.target.value.toLowerCase();
        tableRows.forEach(row => {
            const rowText = row.textContent.toLowerCase();
            if (rowText.includes(searchTerm)) {
                row.style.display = '';
            } else {
                row.style.display = 'none';
            }
        });
    });

    // Chart.js Financials Chart
    const ctx = document.getElementById('financialsChart').getContext('2d');
    const financialsChart = new Chart(ctx, {
        type: 'bar',
        data: {
            labels: ['2024 H1', '2025 H1'],
            datasets: [{
                label: '營收 (億 DKK)',
                data: [1335.7, 1549.4], // 2024 H1 is calculated from 2025 data for comparison
                backgroundColor: 'rgba(59, 130, 246, 0.6)', // blue-500
                borderColor: 'rgba(59, 130, 246, 1)',
                borderWidth: 1
            }, {
                label: '營業利潤 (億 DKK)',
                data: [560, 722], // 2024 H1 profit is estimated
                backgroundColor: 'rgba(22, 163, 74, 0.6)', // green-600
                borderColor: 'rgba(22, 163, 74, 1)',
                borderWidth: 1
            }]
        },
        options: {
            responsive: true,
            maintainAspectRatio: false,
            scales: {
                y: {
                    beginAtZero: true,
                    ticks: {
                        callback: function(value, index, values) {
                            return value + ' 億';
                        }
                    }
                }
            },
            plugins: {
                tooltip: {
                    callbacks: {
                        label: function(context) {
                            let label = context.dataset.label || '';
                            if (label) {
                                label += ': ';
                            }
                            if (context.parsed.y !== null) {
                                label += context.parsed.y + ' 億 DKK';
                            }
                            return label;
                        }
                    }
                }
            }
        }
    });
});
</script>

</body>
</html>